Floatz logo

100 assets in Metastatic Melanoma

Therapeutic assets addressing Metastatic Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Selvigaltin
Metastatic Melanoma
Providence Health & ServicesP2CCC (51)
Poly-Iclc
Metastatic Melanoma
University of Southern CaliforniaP1/2CCC (50)
Mirdametinib
Metastatic Melanoma
Kevin Kim, MDP2CCC (49)
Acetazolamide
Metastatic Melanoma
Obsidian Therapeutics, Inc.P1/2CCC (48)
Emavusertib
Metastatic Melanoma
University of FloridaP1/2CCC (48)
Obx-115
Metastatic Melanoma
Obsidian Therapeutics, Inc.P1/2CCC (48)
Pexastimogene Devacirepvec
Metastatic Melanoma
Lee's Pharmaceutical LimitedP1/2CCC (48)
Socazolimab
Metastatic Melanoma
Lee's Pharmaceutical LimitedP1/2CCC (48)
st-1898 tablets
Metastatic Melanoma
Beijing Scitech-Mq Pharmaceuticals LimitedP1/2CCC (48)
bi-1607
Metastatic Melanoma
BioInvent International ABP1/2CC (47)
anv419
Metastatic Melanoma
Anaveon AGP1/2CC (46)
[203pb]vmt01
Metastatic Melanoma
Perspective TherapeuticsP1/2CC (43)
[212pb]vmt01
Metastatic Melanoma
Perspective TherapeuticsP1/2CC (43)
[225ac]ac-a9-3408
Metastatic Melanoma
Alpha-9 Oncology USA Inc.P1CC (43)
Gotistobart
Metastatic Melanoma
OncoC4, Inc.P1/2CC (43)
Gsk-2636771
Metastatic Melanoma
M.D. Anderson Cancer CenterP1/2CC (43)
Iov-3001
Metastatic Melanoma
Iovance Biotherapeutics, Inc.P1/2CC (43)
Iov-4001
Metastatic Melanoma
Iovance Biotherapeutics, Inc.P1/2CC (43)
Navitoclax
Metastatic Melanoma
National Cancer Institute (NCI)P1/2CC (43)
Ny-Eso-1 Tcr Redirected Autologous T Cell Product
Metastatic Melanoma
Centre Hospitalier Universitaire VaudoisP1CC (43)
Sirolimus
Metastatic Melanoma
National Cancer Institute (NCI)P1/2CC (43)
st101
Metastatic Melanoma
Sapience TherapeuticsP1/2CC (43)
Tazemetostat Hydrobromide
Metastatic Melanoma
National Cancer Institute (NCI)P1/2CC (43)
Tobemstomig
Metastatic Melanoma
Hoffmann-La RocheP1/2CC (43)
Tbio-4101
Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research InstituteP1CC (42)
Tilt-123
Metastatic Melanoma
TILT Biotherapeutics Ltd.P1CC (42)
Bemcentinib
Metastatic Melanoma
BerGenBio ASAP1CC (41)
Adze1.C
Metastatic Melanoma
Adze Biotechnology Australia Pty LtdP1C (39)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes
Metastatic Melanoma
Anusha KalbasiP1C (39)
Autologous Monocyte-Derived Lysate Pulsed Dendritic Cells
Metastatic Melanoma
PrimeVax Immuno-Oncology Inc.P1C (39)
Bavunalimab
Metastatic Melanoma
University of California, San FranciscoP1C (39)
Cdx 1140
Metastatic Melanoma
University of Southern CaliforniaP1C (39)
Cytokine-Induced Memory-Like Natural Killer Cells
Metastatic Melanoma
Washington University School of MedicineP1C (39)
Fludeoxyglucose
Metastatic Melanoma
Anusha KalbasiP1C (39)
Furosemide
Metastatic Melanoma
M.D. Anderson Cancer CenterP1C (39)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells
Metastatic Melanoma
Anusha KalbasiP1C (39)
Ivonescimab
Metastatic Melanoma
Peking University Cancer Hospital & InstituteP1C (39)
Izuralimab
Metastatic Melanoma
University of California, San FranciscoP1C (39)
Mesna
Metastatic Melanoma
M.D. Anderson Cancer CenterP1C (39)
Neovax
Metastatic Melanoma
Dana-Farber Cancer InstituteP1C (39)
pf-08046031
Metastatic Melanoma
PfizerP1C (39)
Quadrivalent Inactivated Influenza Vaccine
Metastatic Melanoma
Carlo ContrerasP1C (39)
Recombinant Flt3 Ligand
Metastatic Melanoma
University of Southern CaliforniaP1C (39)
Secukinumab
Metastatic Melanoma
Duke UniversityP1C (39)
Sonidegib
Metastatic Melanoma
Mayo ClinicP1C (39)
Tacrolimus
Metastatic Melanoma
National Cancer Institute (NCI)P1C (39)
Immunoglobulin G1, Anti-(Human Programmed Death-Ligand 1) (Human Monoclonal Sti-3031 .Gamma.1-Chain), Disulfide With Human Monoclonal Sti-3031 .Lambda.-Chain, Dimer
Metastatic Melanoma
Mayo ClinicP1C (38)
E-6201
Metastatic Melanoma
Mayo ClinicP1D (27)
Crizanlizumab Tmca
Metastatic Melanoma
Sheba Medical CenterP2NR ()
Prifetrastat
Metastatic Melanoma
UNICANCERP2NR ()
Showing 51 to 100 of 100 assets
PreviousPage 2 of 2Next